RK

Rosa Kaviani

Senior Research Engineer at Galvanize Therapeutics, Inc.

Rosa Kaviani has a diverse background in research and business development. Rosa most recently worked at Galvanize Therapeutics, Inc. as a Senior Research Engineer starting in December 2022. Prior to that, they held the role of Business Development Manager at Charles River Laboratories from September 2021 to November 2022. From April 2021 to September 2021, Rosa worked as a Business Development Manager at ITR Laboratories Canada Inc. Before transitioning into business development, they gained experience as a Research Scientist at Charles River Laboratories from January 2019 to March 2021. Rosa also served as a Postdoctoral Fellow at McGill University from March 2016 to December 2018 and as a Graduate Research Assistant at CHU Sainte-Justine Research Centre from September 2011 to February 2016.

Rosa Kaviani has a diverse educational background. Rosa pursued their postgraduate studies in Life Sciences Entrepreneurship at Concordia University from 2020 to 2021. Prior to that, Rosa completed a Postdoctoral Fellowship in Biophysics at McGill University, spanning from 2016 to 2018. Rosa'sacademic journey began at Université de Montréal in 2011, where they obtained their Doctor of Philosophy (Ph.D.) in Bioengineering and Biomedical Engineering, which they completed in 2016.

In addition to their formal education, Rosa has also obtained additional certifications. Rosa obtained a certification in Venture Finance from VC University in May 2023, and a certification in VC Blueprint from Front Row Ventures in January 2022. These certifications complement their educational background and suggest a strong interest in the field of entrepreneurship and venture capital.

Links

Previous companies


Org chart

This person is not in the org chart


Teams


Offices

This person is not in any offices


Galvanize Therapeutics, Inc.

1 followers

Galvanize Therapeutics is an energy-based medical device technology that provides therapeutic products and services to deliver healthcare solutions. The company aims to become the global leader in delivering medical technology innovations that drive biological processes to treat a range of diseases, starting with treating chronic bronchitissymptoms, cardiac arrhythmias, and solid tumors.It was formed by Apple Tree Partners in 2022.


Employees

51-200

Links